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Abstract 11 
The impact of demographic ageing is likely to be of major significance in the coming decades 12 
due to low birth rates and higher life expectancy. Older people generally require more 13 
prescribed medicines due to the presence of multiple conditions such as dysphagia which can 14 
make swallowing medicines challenging. This study involves the development, 15 
characterization and optimization of composite wafers for potential oral and buccal delivery 16 
of low dose aspirin to prevent thrombosis in elderly patients with dysphagia. Blank (BLK) 17 
wafers (no loaded drug) were initially formulated by dissolving combinations of metolose 18 
(MET) with carrageenan (CAR) and MET with low molecular weight chitosan (CS) in 19 
different weight ratios in water, to identify optimum polymer combinations. However, drug 20 
loaded (DL) wafers were prepared using 45% v/v ethanol to help complete solubilization of 21 
the aspirin. The formulations were characterized using texture analyzer (hardness, 22 
mucoadhesion), scanning electron microscopy (SEM), X-ray diffractometry (XRD), 23 
attenuated total reflection – Fourier transform infrared (ATR-FTIR), differential scanning 24 
calorimetry (DSC), thermogravimetric analyzer (TGA), and swelling capacity. Wafers with 25 
higher total polymer concentration were more resistant to penetration (MET:CAR 1:1 26 
samples B2, C2) and MET:CS 1:1 (sample E2) and MET:CS 3:1 (sample F2) and also 27 
depended on the ratios between the polymers used. From the characterization, samples C2, 28 
B2, E2   and F2 showed the most ideal characteristics. XRD showed that BLK wafers were 29 
amorphous, whilst the DL wafers were crystalline due to the presence of aspirin. SEM 30 
confirmed the presence of pores within the polymer matrix of the BLK wafers, whilst DL 31 
wafers showed a more compact polymeric matrix with aspirin dispersed over the surface. The 32 
DL wafers showed a good flexibility required for transportation and patient handling and 33 
showed higher swelling capacity and adhesion values with phosphate buffer saline (PBS) 34 
than with simulated saliva (SS). Drug dissolution studies showed that aspirin was rapidly 35 
released in the first 20 minutes and then continuously over 1 hour. FTIR confirmed the 36 
interaction of aspirin with the polymers evidenced by peak shifts around 1750 cm -1 and the 37 
broad peak between 2500 to3300 cm -1. Lyophilized CAR: CS 1:3 (sample DL13), MET:CS 38 
1:3 (sample DL8) and MET:CAR 3:1 (sample DL1) wafers seem to be a very promising 39 
system for the administration of low dose aspirin for older patients with dysphagia. 40 
 41 
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1. Introduction 44 
 Over the past few decades, there has been an increased interest in novel drug delivery 45 
systems, to improve safety, efficacy and patient compliance and increase the product patent 46 
life cycle (Panda, et al., 2012). Fast dissolving and sustained release lyophilized wafers and 47 
films are examples of novel formulations for oral and buccal mucosa drug delivery and can 48 
be used as fast dissolving oral strips (Peh & Wong , 1999).  49 
 One of the main uses of aspirin is as an anticoagulant to reduce the clotting action of 50 
platelets. This is possible because aspirin exhibits anti-thrombin effect, and administered to 51 
prevent the platelets from aggregating to form blood clots, thus reducing the rate of a heart 52 
attacks and strokes. When aspirin is used this way, it is referred to as ‘low-dose’ aspirin and 53 
normally given at 75mg per dose (single tablet daily). Low dose aspirin is recommended for 54 
people with heart or blood vessel disease and patients who have had heart bypass surgery 55 
(British Medical Association , 2014).  Most people who suffer from these problems are older 56 
(geriatric) patients, who usually also present with other chronic conditions such as dysphagia 57 
(difficulty with swallowing). Dysphagia is an increasing problem among the aging population 58 
who are a growing demographic, especially in developed countries. Therefore alternative 59 
solutions specifically tailored to the special needs of older populations are required by 60 
enhancing the development of novel delivery systems that are easy to administer 61 
(Theodorakis & Guodmundsson , 2012).  62 
 According to  Parkash and colleagues various pharmaceutical preparations used for 63 
geriatric patients are being examined to enhance the treatment compliance and improve the 64 
quality of life for these patients (Parkash, et al., 2011). To mitigate this problem of dysphagia, 65 
fast disintegrating dosage forms such as oral disintegrating tablets, are expected to 66 
disintegrate or dissolve in the oral cavity without drinking water, where they disintegrate to 67 
release the drug and easily drift down along the esophagus with the help of saliva (Kianfar, et 68 
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al., 2011). Using fast disintegrating dosage forms allow rapid therapeutic intervention 69 
because of increased bioavailability arising from the rapid release and rapid absorption 70 
through the oral mucosa, pharynx, and esophagus and eventually through the gastrointestinal 71 
tract. The risk of suffocating during conventional oral administration is also avoided when 72 
using fast disintegrating dosage forms, thus improving patient safety (Parkash, et al., 2011).  73 
 Likewise, oral mucosa delivery approaches, such as sublingual delivery (under the 74 
tongue), buccal delivery, (through the mucosal membranes lining the cheeks) and local 75 
delivery, (Shojaei, 1998), offer advantages for improved drug administration including 76 
prolonged residence time, ease of application and controlled drug release (Ayensu, et al., 77 
2012). These type of dosage forms are convenient not only for elderly patients, but also the 78 
disabled, travelers and busy people who do not always have access to water. There has been 79 
an increased interest in use of the oral mucosa for drug delivery because of its ability to avoid 80 
first pass metabolism in the liver as well as avoiding gastric acid and enzyme degradation in 81 
the stomach and small intestines respectively, which are commonly encountered with the 82 
traditional gastrointestinal oral route (Sattar, et al., 2014). 83 
Wafers can possess adhesive properties when formulated with mucoadhesive 84 
polymers such as low molecular weight chitosan (CS), metolose (MET), carrageenan (CAR). 85 
CS exhibits viscous appearance when hydrated, possesses bioadhesive properties and is 86 
biodegradable and biocompatible with low toxicity (Siriwat, et al., 2012). Degree of 87 
deacetylation (DDA) and molecular weight (MW) of chitosans are important to their physical 88 
and biological properties including crystallinity, degradation, tensile strengths and moisture 89 
contents (Yuan, et al., 2011).  MET is a non-ionic cellulose ether composed of 90 
methylcellulose and three types of HPMC which are available in different grades with 91 
varying viscosities. The most important properties of MET includes solubility in cold water, 92 
development of transparent solutions and viscoelastic properties (Khan, et al., 2016). 93 
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Carrageenan (CAR) is produced from red seaweed (Rhodophyceae) and is a polysaccharide 94 
formed from sulfate group and galactose molecule with a repeating structure of alternating 95 
1,3 – linked D-galactophyranosyl arid 1,4 – linked D-galactophyranosyl units. The 3-linked 96 
units occurs as the 2- and 4- sulfate, or non-sulfate, while the 4-linked units occur as the 2-97 
sulfate, the 2,6 disulfate, the 3,6-anhydride, and the 3,6-anhydride-2-sulfate (Stanley, 2010). 98 
They are classified into different grades, kappa (κ) which has a linear polysaccharide 99 
structure with one sulfate group per two galactose molecules, assuming a helical network 100 
which is strengthened with the presence of potassium ions. Iota (ι), assumes a helical 101 
conformation but with two sulfate groups per two galactose molecules which forms a soft gel 102 
in the presence of calcium ions. Lambda (λ), has three sulfates per two galactose molecules 103 
and does not form a helical structure and does not use ions to achieve a viscous solution 104 
because it is a non-gelling polysaccharide. CAR as natural polymer has not been widely used 105 
in pharmaceutical applications, although there are a lot of published literature reporting on 106 
the use of CAR in the form of wafers and films (Tari, et al., 2009). According to Kianfar and 107 
co-workers, buccal wafers were obtained by freeze drying gels combining 2% (w/w) k-108 
CAR911 and 4% (w/w) Pluronic F127 incorporating 4.4% (w/w) PEG 600 as well as 0.8% 109 
(w/w) ibuprofen or 1.8% (w/w) paracetamol.  The texture analysis  for these wafers showed 110 
ideal mechanical and mucoadhesion characteristics whilst both drugs remained stable over 6 111 
months and drug dissolution at salivary pH showed gradual release within 2 hours, which 112 
demonstrate the potential of CAR and pluronic F127 based wafers for buccal mucosa drug 113 
delivery (Kianfar et al, 2011, 2013). κ-carrageenan was selected due to the availability of 114 
various sites for hydrogens bonding which improves bioadhesive properties to the 115 
formulation, as well as, increase in drug bioavailability (Thommes & Kleinebudde, 2006).  116 
 The current paper describes the formulation development, characterization and 117 
optimization of composite MET:CAR and MET:CS lyophilized wafers as drug delivery 118 
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systems via both the oral route and buccal mucosa membrane for potential administration of 119 
low dose aspirin to geriatric patients with dysphagia. The formulations have been 120 
functionally characterized using texture analysis, X-ray diffraction (XRD), scanning electron 121 
microscopy (SEM), attenuated total reflectance  – Fourier transform infrared (ATR-FTIR) 122 
spectroscopy, differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) 123 
for hardness, mucoadhesion, surface and internal morphology, crystallinity, chemical 124 
interactions and thermal behavior respectively. The characterization results were used to 125 
compare the properties of MET:CAR and MET:CS wafers to determine which could be 126 
suitable for controlled release via buccal mucosa absorption or as fast disintegration dosage 127 
forms for easy swallowing.  128 
 129 
2. Materials and methods  130 
2.1 Materials 131 
 `Metolose (MET) was obtained as a gift from Shin Etsu (Stevenage, Hertfordshire, 132 
UK), polyethylene glycol (PEG 400), gelatin and mucin from bovine submaxillary gland 133 
were obtained from Sigma-Aldrich (Gillingham, UK), carrageenan (CAR) low viscosity 134 
grade NF 911 (κ), molecular weight less than 100,000 Da, 25% sulfate esters, stable at pH 135 
values > 3.8 was obtained as a gift from IMCD Ltd (Sutton, UK), low molecular weight 136 
chitosan (CS) with 95% degree of deacetylation and MW of 3000 Da .obtained from Qingdao 137 
Yuda Century Economy and Trade CO, Ltd (China), calcium chloride, sodium chloride, 138 
sodium phosphate dibasic, magnesium chloride hexahydrate, potassium carbonate 139 
hemihydrate and sodium phosphate monobasic monohydrate were obtained from Fischer 140 
Scientific (Loughborough, UK).  141 
 142 
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2.2 Formulation optimization  143 
2.2.1 Preliminary development of composite BLK wafers 144 
Prior to drug loading, preliminary investigations were undertaken by preparing composite 145 
blank (BLK) wafers by freeze-drying their aqueous solutions combining MET with CAR 146 
(MET:CAR) and MET with CS (MET:CS) in different weight ratios. This was to identify a 147 
suitable number of formulations as composite combinations as part of the development and 148 
optimization process. The composite gels were prepared by simply dispersing MET:CAR, 149 
MET:CS in deionized water and magnetically stirred till homogeneous solutions were 150 
obtained. The concentrations prepared are summarized in table 1 a). 1g of each initial BLK 151 
composite polymer solution was poured into each well of a 24 multi-well plate (diameter 15.5 152 
mm). The freeze-dried process was conducted by an automated lyophilization cycle on a 153 
Virtis Advantage XL 70 freeze-dryer (Biopharma process systems, Winchester, UK). In the 154 
freezing steps the samples were  cooled from room temperature to 5 °C for 40 minutes, 5 °C 155 
to – 10 °C for 40 minutes and -10 °C to -55 °C for 120 minutes. An annealing process was 156 
integrated into the freezing cycle to boost pore size distribution by increasing the temperature 157 
from – 55 °C to – 35 °C over 2 hours and cooling back to – 55 °C over 3 hours and 158 
maintained at -55 °C over 1 hour with a condenser temperature of – 55 °C and pressure of 159 
200mTorr was implemented to assure uniformity. A pressure of 50mTorr, with temperature 160 
increased from -55 °C to – 20 °C during 8 hours and further increased from – 20 °C to – 15 161 
°C during 10 hours was applied during the primary drying stage. The secondary drying 162 
happened at the same pressure as primary drying and the temperature was raised from – 15 163 
°C to 25 °C over 12 hours 30 minutes. Heat was applied in this step to remove the amount of 164 
water molecules remained during primary drying after the free ice sublimed (Nireesha, et al., 165 
2013) (Okeke & Boateng, 2016). BLK formulations were not prepared in ethanol as the 166 
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polymers used were water soluble. Ethanol was only used in the DL formulations as part of 167 
further development to help the solubility of aspirin which is a hydrophobic drug.  168 
  169 
2.2.2 Formulation of drug loaded wafers 170 
The drug loaded (DL) composite wafers were prepared by freeze-drying solutions combining 171 
MET with CAR and MET with CS in different weight ratios with each wafer loaded with 75 172 
mg of aspirin. The various DL wafers prepared are summarized in (table 1 b). During the 173 
drug loading many problems arose including precipitation of aspirin from the aqueous 174 
polymer solutions and poor physical properties of the resulting wafers. Therefore ethanol at 175 
different concentrations (v/v) and composite formulations comprising two or three polymers 176 
were investigated as part of further optimization to obtain DL wafers with the ideal physical 177 
properties.  178 
After the preparation of the optimized composite DL polymeric solutions, (1g) was poured 179 
into each well of a 24 multi-well plate (diameter 15.5mm) with 75 mg of aspirin per well. To 180 
obtain 75 mg per well, the dose was multiplied by the amount of DL solution to be prepared. 181 
In a 100 g solution, 7500 mg of aspirin was needed, so that 1 g of solution theoretically 182 
contained 75 mg of aspirin. Prior to freeze-drying, the aspirin loaded polymer solutions were 183 
frozen in a -80°C freezer to reduce the length of time aspirin remained in an aqueous liquid 184 
environment, owing to its known susceptibility to hydrolysis. The samples were then 185 
subjected to the freeze-drying cycle as described for the BLK wafers (section 2.2.1), but 186 
without the annealing step. 187 
2.3 Texture analysis 188 
Texture analyzer (HD plus, Stable Micro System, Surrey, UK) fitted with a 5 kg load 189 
cell, was used to analyze the mechanical and mucoadhesion properties of the wafers. The 190 
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software Texture Exponent 32® was used to collect and process the data from the texture 191 
analyzer. Three replicates (n = 3) were performed for each sample.  192 
 193 
2.3.1 Mechanical properties of wafers  194 
The resistance of the wafers to deformation, referred to as ‘hardness’ was measured 195 
with the instrument in compression mode. Each wafer was compressed in 5 different 196 
positions (n = 3), using a 2mm cylinder stainless steel probe to a depth of 1mm and speed of 197 
1 mm/sec.  198 
2.3.2 Mucoadhesion studies 199 
The wafers were attached to an adhesive probe (35 mm diameter) using double-sided 200 
adhesive tape. Gelatin gel [6.67% (w/v)], representing the buccal mucosa surface, was 201 
prepared by dissolving the gelatin in 70 °C water. 20 ml of the resulting hot solution were 202 
transferred into Petri dishes (86 mm diameter) and left in the fridge overnight to set into a 203 
solid gel. Before performing the mucoadhesion, 500 µl of PBS pH 6.8 ± 0.1 or simulated 204 
saliva (SS) at pH 6.8 ± 0.1 were spread over the surface of the gelatin to mimic the buccal 205 
mucosa more accurately. The [0.01 M PBS (pH 6.8 ± 0.1)] was prepared by dissolving 6.80 g 206 
of potassium dihydrogen phosphate in 1L of deionized water and adjusting the pH 6.8 ± 0.1 207 
using sodium hydroxide (Boateng & Ayensu, 2014). The SS was prepared by dissolving 208 
calcium chloride dehydrate (0.228 g), sodium chloride (1.017 g), sodium phosphate dibasic 209 
(0.204 g), magnesium chloride hexahydrate (0.061 g), potassium carbonate hemihydrate 210 
(0.603 g), sodium phosphate monobasic monohydrate (0.273 g) and submaxillary mucin 211 
(1.000 g) in 1L of deionized water (Marques, et al., 2011). The probe with the wafers 212 
attached was lowered to make contact with the model mucosa surface with an applied force 213 
of 1.0 N and was detached after 60 seconds of contact. The mucoadhesion strength was 214 
determined by the maximum adhesive force (Fmax) necessary to detach the sample from the 215 
10 
 
model buccal surface. The work of adhesion was determined by the area under the force-216 
distance curve and cohesiveness by the distance the wafers travelled before detaching from 217 
the gelatin surface.  218 
 219 
2.4 Swelling capacity 220 
The swelling capacity of the BLK and DL wafers was determined in two different 221 
media [(0.01M PBS solution (pH 6.8 ± 0.1) and (SS) (pH 6.8 ± 0.1)] and both set at a 222 
temperature of 37 ± 0.1°C. The wafers were immersed into 5 ml of the PBS or SS and the 223 
percentage swelling capacity was determined by recording the change in weight at specific 224 
time intervals up to 120 minutes. For every time point, the media was removed to obtain an 225 
accurate weight of the sample and replaced with fresh media. The swelling capacity were 226 
determined for three replicates (n = 3) and calculated using equation 1 (Okeke & Boateng, 227 
2016).  228 
Swelling index = 
𝑊𝑠−𝑊𝑑 
𝑊𝑑
 x 100                                                                            (Equation 1)      229 
where; Wd = dry weight of wafers; Ws = weight of wafers after swelling  230 
 231 
2.5 Scanning electron microscopy (SEM) 232 
The surface morphology of the BLK and DL wafers were analyzed using a Hitachi 233 
SU8030 (Hitachi High-Technologies, Krefeld, Germany). The wafers were cut into small 234 
pieces and placed on Agar Scientific G301 aluminium pin-type stubs, using Agar Scientific 235 
G3347N double-sided adhesive carbon tape. The wafers were gold coated for clearer pore 236 
image using a Sputter Coater (Edwards 188 Sputter Coater S1508) and analyzed at 5.0 kV 237 
accelerating voltage.  238 
 239 
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2.6 Pore analysis       240 
Pore analysis by a solvent displacement method was used to determine the porosity of 241 
the composite wafer structure. The wafers were initially weighed and then immersed in 10 ml 242 
of ethanol in a 20 ml measuring cup, covered and left to stand for 2 hours for complete 243 
saturation. Then, the set up was degassed to remove all air bubbles from the wafers, sample 244 
removed from the solvent, quickly wiped to remove excess solvent and immediately re-245 
weighed to avoid the loss of ethanol which is volatile. The porosity (%) of wafers were 246 
determined for three replicates (n = 3) and calculated using equation 2 (Okeke & Boateng, 247 
2016). 248 
P = 
𝑉𝑝
𝑉𝑔
 x 100 = 
𝑊𝑓−𝑊𝑖
𝑃𝑒𝑉𝑔
        (Equation 2) 249 
where; Vp = pore volume 250 
            Vg = wafers geometrical volume 251 
             Wf = final weight of wafer 252 
             Wi = initial weight of wafer  253 
              ρe = ethanol density (0.789 g/cm3)  254 
 255 
2.7 X-ray diffraction (XRD)  256 
X-ray diffraction was used to determine the physical form (crystalline/amorphous) of 257 
the BLK and DL wafers using a D8 Advantage X-ray diffractometer. Wafers were 258 
compressed using two clean glasses, placed on the holder and mounted on the sample cell. 259 
For pure compounds, Mylar was used to hold the powders before placing on the sample cell. 260 
The samples were analyzed in transmission mode at diffraction angle range of 5° to 50° 2θ, 261 
step size 0.04°, and scan speed of 0.4 s/step.  262 
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 263 
2.8 Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 264 
analysis 265 
ATR-FTIR spectra were obtained from a Perkin Elmer Spectrum instrument equipped 266 
with a diamond universal ATR unit. The composite BLK and DL wafers were cut into small 267 
pieces and placed on the ATR diamond crystal. Force was applied using the pressure clamp 268 
to allow suitable contact between the samples and the diamond crystal. The resolution of the 269 
samples were recorded at 4 cm-1 within the range of 500-4000 cm-1. Background spectra were 270 
subtracted in order to obtain a consistent absorbance of each sample. Pure compounds were 271 
analyzed by placing a small amount of the polymer on the ATR diamond crystal followed by 272 
the same process used for analyzing wafers.  273 
 274 
2.9 Thermogravimetric analysis (TGA) 275 
TGA studies were performed using a Q5000 (TA Instruments, New Castle, DE, US) 276 
thermogravimetric analyzer to determine the residual moisture content (%), dynamic weight 277 
loss and degradation temperature of the pure polymers, BLK and DL wafers. About 1 to 2 mg 278 
of the wafers and the pure compounds was placed into hermetically sealed Tzero aluminium 279 
pans. The samples were heated under nitrogen gas at a flow rate of 25 mL/min, from 20 to 280 
300 °C at a heating rate of 10 °C/min.  281 
 282 
2.10 Differential scanning calorimetry (DSC) 283 
A DSC Mettler Toledo instrument was used to thermally evaluate the pure 284 
compounds, the BLK and DL wafers. The samples  were weighed (between 2 and 5 mg), 285 
placed in Tzero pans and covered with Tzero hermetic lids and heated from – 25 °C to 250 286 
°C at the rate of 10 °C/min under continuous stream of nitrogen.  287 
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 288 
2.11 In vitro drug release 289 
In vitro drug dissolution of aspirin loaded (DL) wafers was performed using a Franz-290 
diffusion cell apparatus. The receptor compartment was filled with 8 ml of two different 291 
media [(0.01M PBS solution (pH 6.8 ± 0.1) and SS (pH 6.8 ± 0.1)] with a mesh (1 mm mesh 292 
size) on the receptor surface. The donor and receptor compartments were sealed with paraffin 293 
to limit evaporation and held together by a pinch clamp. The system was placed on a water 294 
bath at 37 °C and magnetically stirred (200 rpm). Formulations were cut, accurately weighed 295 
(20-40 mg) and placed on the mesh between the donor and receptor compartments such that 296 
the dissolution medium just wet once side of the wafer sample. At predetermined time 297 
intervals, 0.5 ml aliquots of the dissolution media were withdrawn using a 1 ml syringe, 298 
filtered through a 0.45 µm cellulose acetate membrane, transferred into HPLC vials and 299 
analyzed using HPLC. The aliquot withdrawn was always replaced with fresh dissolution 300 
medium at 37 °C. The percentage cumulative drug released from the wafers were calculated 301 
and plotted against time (n = 3). The dissolution data were fitted to the Korsmeyer-Peppas 302 
equation to determine mechanisms of drug release (Khan et al, 2015) (see supplementary data 303 
S1).  304 
 305 
2.12 Statistical analysis  306 
Statistical analysis was carried out to compare swelling capacity %, mucoadhesion, hardness, 307 
porosity and drug release of wafers using two tailed student t-test with 95% confidence 308 
interval (p-value < 0.05) as the minimum level of significance. All the experiments were 309 
carried out in triplicates for all experiments with mean and standard deviation.  310 
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3. Results and discussion  311 
3.1 Optimization of formulations   312 
The BLK and the DL formulations were optimized separately because preliminary 313 
studies were carried out in order to analyze the physical and chemical properties of the 314 
composite polymer formulations. The objective of the preliminary study was to develop an 315 
elegant and physically stable formulation showing compatibility between the combined 316 
polymers prior to drug loading (Shimoyamada, et al., 1994). The ratios of polymers were 317 
optimized in order to obtain a composite formulation with enhanced characteristics compared 318 
to that achieved by the individual polymers. The composite formulations were preferred as 319 
they possessed enhanced characteristics from both polymer, such as mucoadhesion and 320 
mechanical strength In this study the ratios for MET:CAR, CAR:CS and MET:CS were 321 
chosen from 1:3, 1:1 and 3:1 to determine the best combinations with ideal characteristics for 322 
loading the drug.  323 
The BLK wafers prepared from MET:CAR 1:1 (sample B2), MET:CAR 3:1 (sample 324 
C2) and MET:CS 1:1 (sample E2) and MET:CS 3:1 (sample F2) gels  were easily removed 325 
from the well plates, easy to handle and remained intact when removed from the mold. 326 
However, the wafers prepared from MET:CAR (samples A1 and A2) and MET:CS (samples 327 
D1 and D2) in the ratio 1:3 were weaker, brittle and easily deformed when handled. 328 
Therefore, samples A1, A2, D1 and D2 were tested by texture analyzer to confirm 329 
mechanical properties. Wafers prepared from MET:CAR and MET:CS (samples A, B, C, D, 330 
E and F) gels at any combination ratio showed the same weak characteristics of the wafers 331 
described above, but they were also tested for mechanical characteristics for confirmation of 332 
their weakness.  333 
 Though the BLK formulations prepared from gels composed of MET:CS ratio 3:1 and 334 
1:1 (sample F2 and E2) showed ideal characteristics and initially attempted for drug loading, 335 
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this was challenging due to precipitation of the drug from the aqueous gels. This is due to the 336 
fact that only 3 mg/ml of aspirin dissolves in water which was far below what was required to 337 
ensure the formulation of low dose aspirin wafers containing  75 mg of the drug similar to the 338 
low dose aspirin tablets currently available in the market. Various combinations of 339 
ethanol/water were prepared to determine the minimum volume of ethanol required to 340 
completely dissolve the aspirin and 45% v/v ethanol was the minimum necessary for the 341 
aspirin to completely dissolve in the gels.  However, the addition of ethanol affected the 342 
freezing procedure originally optimized for preparing the BLK wafers. This is because 343 
though organic solvents, are removed during the primary drying step, lower temperatures are 344 
required to freeze and condense solvents, compared to water. To resolve this challenge, the 345 
annealing step for the freeze-drying cycle used in preparing the BLK formulations was 346 
removed during formulation of the DL wafers, with the lowest freezing temperature 347 
maintained at -55 °C for 6 hours instead (Barley, 2009). 348 
Further, the use of ethanol also affected the physical behavior of the DL wafers obtained by 349 
loading aspirin into the originally optimized BLK gels. As a result, further formulation 350 
development of MET:CS and MET:CAR gels containing higher total polymer, in different 351 
ratios, were formulated to further optimize the DL wafers. Therefore, wafers prepared from 352 
MET:CAR gels in the ratio 3:1 and 1:1 (samples DL1 and DL2) and those prepared from 353 
CAR:CS 1:1 and 1:3 (samples DL14 and DL13) and MET:CS 1:3 (sample DL8) were tested 354 
with texture analyzer to confirm their ideal mechanical characteristics.  355 
 356 
3.2 Texture analysis (TA) 357 
 3.2.1 Mechanical properties of the wafers 358 
The resistance to deformation of wafers is an important functional characteristic, as it 359 
affects the performance of the wafers in terms of ease of handling and application without 360 
16 
 
damaging the formulation, which is important to guarantee consistent dosing between 361 
administrations (Boateng et al., 2010, Kianfar et al., 2014). Figure 1a shows the hardness 362 
(resistance to compressive deformation) profiles of wafers prepared from MET:CS at 363 
different polymer ratios and different total polymer content within the original gels. The 364 
wafers prepared from MET:CS gels in the ratios 1:3, 1:1 and 3:1 (samples D, E, and F) 365 
showed a very low hardness profile compared to those containing higher total polymer 366 
content due to lower matrix density of the former. MET:CS ratio 1:3 (sample D2) showed a 367 
hardness of 0.42 ± 0.02 N while ratio 3:1 (sample F2) showed a hardness of 0.35 ± 0.15 N 368 
and 1.5% (w/v) MET:CS ratio 1:1 (sample E) had a hardness of 0.77 ± 0.16 N. Further, 369 
MET:CS ratios 1:3, 1:1 and 3:1 (samples D1, E1 and F1) which had a total solids content of 370 
2% per 100g of gel, showed similar trends to MET:CS wafers containing total solids content 371 
of 2% per 100g of gel with hardness values of 1.20 ± 0.08 N, 1.23 ± 0.52 N and 0.88 ± 0.19 372 
N, respectively. The hardness of MET:CS ratio 1:3 (sample D2) showed a value of 1.88 ± 373 
0.76 N, ratio 1:1 (sample E2) was 2.69 ± 0.28 N and ratio 3:1 (sample F2) was 2.86 ± 0.28 N.  374 
 The results generally demonstrated that as the concentration of MET increased within 375 
the formulation, the hardness of the wafers also increased though they remained non-brittle. 376 
The reason was that as the polymer content increased, the resulting gels became more viscous 377 
and produced more stable, stronger, compact (denser) wafers after freeze-drying. However, 378 
the wafers with higher ratios of CS were very brittle and flaky and difficult to remove for 379 
testing. These observations suggest that MET:CS 1:1 and 3:1 (samples E2 and F2) were ideal 380 
formulations for loading aspirin, compared to the wafers prepared from gels containing lower 381 
total polymer content such as samples D, E and F   which deformed easily during removal 382 
and handling.  Sample D2 had a lower hardness profile compared to sample E2 and F2due to 383 
the lower amounts of MET as previously noted. 384 
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 Figure 1 b shows the hardness profiles of composite MET:CAR wafers in the ratio 385 
1:3, 1:1 and 3:1 (samples A, B, C, A1, B1, C1, A2, B2 and C2). As was the case for MET:CS 386 
wafers, the hardness profiles were higher as the ratio of MET increased within the 387 
formulation. The wafers prepared from MET:CAR 1:3 (sample A) had a hardness of 0.24 ± 388 
0.06 N, whereas ratio MET:CAR 3:1 (samples C) had a value of 1.25 ± 0.12 N. The hardness 389 
of sample A1  was 0.25 ± 0.02 N, and sample B1 was 0.37 ± 0.02 and sample C1 was 2.60 ± 390 
0.04 N. Although, samples C and C1  had higher hardness values, these were lower compared 391 
to samples C2 which showed a hardness of 3.57 ± 0.09, which should be an ideal candidate 392 
for controlled release of drug.   393 
 Comparing MET:CS and MET:CAR wafers, it was demonstrated that MET:CAR 394 
formulations were stronger and more resistant to compressive deformation than MET:CS 395 
wafers due to the functional and physical properties of CAR which possess stabilizing, 396 
gelling and thickening ability (Pairatwachapun, et al., 2016). Due to the high robustness, 397 
good compatibility and persistent viscoelasticity, CAR has also been used in tablets as 398 
excipient for sustained release formulations (Zia, et al., 2017) due to its ability produce 399 
stronger formulations. On the other hand, MET:CS formulations were weaker and brittle due 400 
to highly water soluble nature of soluble CS and therefore unable to swell to form stable gels.  401 
 Figure 1 c shows the hardness profiles of DL MET:CAR 3:1 (sample DL1)   CAR:CS 402 
1:3 (sample DL13) and CS:CS 1:1 (sample DL14) wafers  and MET:CS ratios 1:3 and 1:1 403 
(samples DL8 and DL7) wafers . The DL wafer obtained from MET:CAR 3:1 gels (sample 404 
DL1) showed the highest hardness value of 5.19 ± 0.03 N and the sample DL2  prepared 405 
from MET:CAR 1:1 showed a lower hardness value of 1.58 ± 0.14 N. This shows that 406 
increasing MET content when in combination with CAR results in a higher resistance to 407 
deformation under compression.  408 
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Comparing the DL formulations with the BLK, there was an increase in hardness for 409 
sample DL2 and sample DL1. This increase can be attributed to the decreased porosity of the 410 
wafers due to the added drug and subsequent salt formation including salicylates.  411 
 Generally, the hardness of the wafers affects the swelling profile of the wafers 412 
(Campo, et al., 2009) because wafers with a higher hardness profiles means that the porous 413 
matrix is more compacted (see SEM results) and less able to swell which impacts on the rate 414 
of drug diffusion.  415 
 416 
3.2.2 In vitro mucoadhesion  417 
One of the objectives of the current study, was to explore use of freeze-dried wafers to 418 
deliver low dose aspirin for patients with dysphagia as an alternative to currently used oral 419 
tablets, either as rapid disintegration matrix that is easily swallowed (gastric absorption) or 420 
formulations that can remain long enough in the buccal region to allow pregastric absorption, 421 
followed by swallowing of the remaining free flowing gel. Therefore, it was important to 422 
determine the mucoadhesion behavior of the formulated wafers. There are different theories 423 
to explain the mucoadhesion process (Smart, 2005). Mucoadhesive bond formation involves 424 
wetting and swelling of the polymer network arising from intimate contact between the 425 
substrate and dissolution fluid such as PBS or SS followed by interpenetration and 426 
entanglement between polymer chains and the mucosal substrate (Sriamornsak, et al., 2008).  427 
Figure 2a – b shows the mucoadhesion profiles of BLK MET:CAR and MET:CS wafers 428 
obtained from the texture analyzer. Figure 2 a showed that the peak adhesion force (PAF) in 429 
PBS for MET:CAR formulations was higher when the ratio was 1:1 with value of 0.54 ± 0.05 430 
N for sample B1 and 0.54 ± 0.01 N for sample B2. The PAF for the wafers composed of 431 
MET:CAR ratio 3:1 (samples C1 and C2) also showed higher values at 0.52 ± 0.13 N and 432 
0.41 ± 0.01 N, respectively, compared with MET:CAR 1:3 (samples A1 and A2). . Samples 433 
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A1 showed higher TWA values of 1.11 ± 0.20 N mm  and 0.53 ± 0.32 N mm for sample A2  434 
compared to samples B1, C1, B2 and C2  with TWA values of 0.43 ± 0.01, 0.44 ± 0.01 N 435 
mm and 0.19 ± 0.07, 0.21 ± 0.01 N mm respectively. The increase in the TWA for samples 436 
A1 and A2  wafers is attributed to the higher concentration of CAR in the formulations which 437 
impart bioadhesive properties by the availability of several sites for hydrogen bonding. In 438 
addition, CAR enhances the mucoadhesive properties by the negative charge of the sulfate 439 
group in its structure forming ionic bonds with the positively charged mucin present on the 440 
model buccal mucosa membrane (Kianfar, et al., 2011). 441 
The cohesiveness values were also affected by the different ratios and total polymer content. 442 
Sample A1  showed the highest cohesiveness of 4.84 ± 0.61 mm which was  decreased to 443 
0.63 ± 0.02 mm for sample C1. For sample A2, the cohesiveness was 2.46 ± 0.38 mm but 444 
decreased to 0.87 ± 0.03 for sample C2 due the CAR characteristics explained above. The 445 
cohesiveness in the SS decreased when compared with PBS, and there was a slight difference 446 
between the cohesiveness for sample A1 with values within 1.31 ± 0.38 mm  increasing 447 
slightly to 1.38 ± 0.09 mm for sample C1  in SS. For sample A2 there was a decrease from 448 
2.46 ± 0.38 mm  to 0.87 ± 0.03 mm for sample C2. The TWA for SS increased from 0.15 ± 449 
0.03 N mm  for sample A1 to 0.45 ± 0.12 N mm in sample C1.. Similar values were obtained 450 
for samples A2 and C2. .  451 
Figure 2b shows the mucoadhesive profiles of MET:CS wafers obtained from gels 452 
containing total polymer solids of 2.0 and 2.5% in the gels. The PAF and TWA increased 453 
with increased amounts of MET with a maximum PAF value of 0.41 ± 0.01 N for sample F1 454 
and 0.48 ± 0.06 N for sample F2 in both PBS and SS.  The TWA increased from 0.16 ± 0.01 455 
N mm in sample D1 to 0.29 ± 0.05 N mm in sample F2. However, the cohesiveness for 456 
samples D1, E1, F1, D2, E2 and F2  in PBS were very similar to SS and was not affected by 457 
the total polymer content or weight ratios. This could be because cohesiveness represents the 458 
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distance travelled by the wafer before being detached from the model mucosa surface, and 459 
mainly a function of the actual polymer contents rather than how much was present. The 460 
latter impacts on the initial rate of hydration which affects PAF and TWA more than 461 
cohesiveness (Boateng and Ayensu, 2014). 462 
 Figure 3a - b shows the mucoadhesion profiles of DL composite wafers prepared 463 
from MET:CAR 1:1 (sample DL2) and 3:1 (sample DL3), CAR:CS 1:3 (sample DL13) and 464 
1:1 (sample DL14) and MET:CS ratio 1:3 (sample DL8) in the two different media. The 465 
results showed a similar behavior to the corresponding BLK wafers (figure 2 a) with a 466 
decrease in PAF, cohesiveness and TWA for the formulations containing lower amounts of 467 
MET in the case of MET:CAR wafers and a decrease in PAF and TWA for MET:CS 468 
formulations as the CS ratio increased. However, in the case of CAR:CS formulations, there 469 
was an increase in cohesiveness from 0.73 ± 0.11 mm to 1.14 ± 0.11 mm as the ratio of CS 470 
increased which can be attributed to the fact that increasing amount of CS in CAR:CS 471 
formulations allows easier formation of a gel like structure upon hydration and helps more 472 
intimate contact with the substrate. According to Tobyn et al. (1997), increasing ionic 473 
strength of the media and the presence of sodium and potassium ions results in decreased 474 
adhesion when the amount of CAR is higher in the formulation.  475 
   476 
The effect of ionic strength and pH on swelling and mucoadhesion of polymer 477 
matrices has been described by (Park & Robinson, 1985). They found out that the strength of 478 
mucoadhesion attraction at the mucosal membrane for polymers possessing carboxyl groups 479 
were much stronger than that those with neutral functional groups such as non-polar 480 
polymers. The pH of the saliva as medium affects the behaviors of the polymer depending on 481 
the salivary flow rate and method used to determine it. The pH of the surrounding medium to 482 
which mucoadhesive polymers come in contact can alter the ionization state and the adhesion 483 
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properties of the polymers. This could explain the differences and similarities observed in the 484 
mucoadhesion profiles in the two different media (SS and PBS), however, SS is the most 485 
realistic media simulating in vivo conditions more closely. 486 
 487 
3.3 Swelling studies 488 
For hydrophilic polymer based matrices such as the composite wafers formulated in 489 
the current study, the swelling is an important characteristic, as it affects other functional 490 
properties, including mucoadhesion, rate of disintegration, drug dissolution and eventual 491 
release from the swollen or eroded matrix. It depends on several physical properties of the 492 
matrix, including porosity, matrix density and mechanical strength. During swelling, polymer 493 
chains absorb moisture, and converted from glassy state to the rubbery state, resulting in 494 
increased chain mobility, which allows dissolution of dispersed drug and its subsequent 495 
diffusion out of the swollen matrix. The swelling also depends on other external factors such 496 
as pH, ionic strength and total volume of the dissolution medium, therefore the % swelling 497 
capacity (index) of the wafers was also determined in two different media i.e. SS and PBS.  498 
The % swelling index for MET:CS 3:1 wafers (samples C1 and C2) was observed to 499 
be 849 ± 62.88% and 803 ± 91.50% in SS (Figure 4a) and higher at 1413 ± 240% and 914 ± 500 
168% in PBS for MET:CS 3:1 wafers i.e. samples C1 and C2 respectively (Figure 4b). 501 
Samples C1 and C2 had a higher swelling capacity over a longer period compared to  502 
MET:CS 1:1 and 1:3 wafers (samples B1, A1) and MET:CS 1:1 and 1:3 (samples B2 and A2) 503 
which is attributed to the higher amount of MET in the formulation. Samples D1 and D2 had 504 
very low swelling capacity and disintegrated within seconds after being placed in SS due to 505 
the lower amounts of the swellable MET.   506 
However, samples A1 and A2 showed a higher % swelling capacity  compared to samples 507 
B1, B2, C1 and C2  which is attributed to the higher ratio of MET in the formulations, due to 508 
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the higher density of MET in the wafers and corresponded with their higher resistance to 509 
compression. 510 
 The % swelling capacity for MET:CAR 1:3 wafers (samples A1 and A2) were 2822 ± 511 
60% and 2257 ± 183% respectively within 5 minutes in SS (Figure 4c). These wafers had 512 
higher ability to swell in SS compared to the others due to the higher ratio of CAR which 513 
increases pore sizes and its distributions thus increasing the rate of water ingress (hydration) 514 
and subsequently % swelling capacity. In figure 4 c it can be observed that the MET:CAR 1:1 515 
and 3:1 wafers (samples B1, B2, C1 and C2) had longer swelling duration of about 120 516 
minutes and lower swelling capacity which is due to the higher concentrations of MET which 517 
act as a stabilizer for the wafers  (Shin Etsu Chemical, 2005). In SS the swelling profile of  518 
MET:CAR 3:1,1:1 and 1:3 (samples A1, B1, C1, A2, B2 and C2) were lower than when 519 
performed in PBS (Figure 4d) which could be due to the difference in ionic strength of the 520 
media and that plays an important role in the swelling of the wafers (Khan, et al., 2016). 521 
These characteristics confirm the MET:CAR wafers as potentially suitable for a controlled 522 
release of the low dose aspirin and the MET:CS suitable as a fast disintegrating wafers as 523 
observed during the mechanical testing.   524 
 The swelling capacity (%) in PBS (Figure 5a) for the DL wafers prepared from 525 
MET:CAR 3:1 and 1:1 (samples DL1 and DL2) gels showed the highest swelling capacity of 526 
313 ± 21 and 540 ± 40 % respectively. They were able to maintain their structural integrity at 527 
the beginning of the experiment, but after 30 minutes they lost their integrity because of 528 
excessive absorption of water molecules. Between the wafers produced from CAR:CS 1:3 529 
and 1:1 (samples DL14 and DL13) a fast disintegration of the DL wafers were observed 530 
within 2 minutes with maximum swelling capacity of 154 ± 10 % and 215 ± 23 % 531 
respectively. This showed that as the concentration of CAR increased, the swelling capacity 532 
increased and this was similar for MET:CAR 1:1 and 3:1 wafer (samples DL1 and DL2). 533 
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Figure 5b shows the swelling capacity % of the DL wafers in SS. The results shows similar 534 
profiles for the wafers produced from MET:CAR 3:1 and 1:1 (samples DL1 and DL2) with a 535 
decrease in the swelling capacity as MET concentration increased, at 302 ± 52 %  and 527 ± 536 
69 respectively. The rate of swelling of MET:CAR wafers in PBS was higher than the rate of 537 
swelling in SS media indicating that MET:CAR wafers exhibited faster rate of water uptake 538 
and hydration in PBS than in SS.   539 
 Generally the BLK samples A2 and C2  showed higher % swelling capacity compared 540 
to the corresponding DL samples DL1 and DL2 in both media.  The reason behind the BLK 541 
wafers showing higher swelling capacity (%) compared to DL wafers is due to the formation 542 
of sodium sulfate in the latter which affects their swelling capacity (Khan, et al., 2016). 543 
Further, the swelling capacity values were lower in SS when compared with PBS which can 544 
be attributed to the difference in ionic strength of the media which plays an important role in 545 
the swelling profile of porous formulations such as wafers (Peh & Wong, 1999).  546 
 547 
3.4 Scanning electron microscopy 548 
Figure 6a - d showed a porous sponge-like micro structure for the MET:CAR wafers resulting 549 
from the sublimation of water during freeze-drying process. Samples A, B, C, A1, B1, C1, 550 
A2, B2 and C2 showed collapsed pore walls as the concentration of MET increased with the 551 
most collapsed walls observed in samples C1 and C2. Figure 6e - h show the surface 552 
morphology of BLK MET:CS wafers which also demonstrated a sponge-like and porous 553 
structure, and showed highly collapsed pore walls irrespective of the different polymer ratios 554 
which is attributed to the presence of a low molecular weight compound (soluble CS) which 555 
has high affinity for water therefore affecting ice crystal formation and crystal size during the 556 
freeze drying process, and therefore pore size which subsequently affects rate of hydration, 557 
swelling, mucoadhesion and drug release.  558 
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 Although, the BLK MET:CAR wafers showed smaller pores that were more 559 
uniformly distributed compared to MET:CS wafers, the BLK MET:CS wafers were more 560 
brittle in appearance compared with BLK MET:CAR which can be attributed to the presence 561 
of sub pores. This explains the reason of MET:CAR formulations being more resistant to 562 
deformation (hardness) than MET:CS wafers. 563 
 Figure 7a shows the surface features of the aspirin crystals at x30 magnification. It 564 
was observed that the aspirin crystal is smooth and that small crystallites were found on the 565 
surfaces. Figures 7b - e showed the surface morphology of the aspirin loaded wafers (samples 566 
DL1, DL2, DL8, DL13 and DL14  respectively. These DL wafers showed a very compact 567 
polymer matrix structure with crystals of aspirin distributed over their surfaces. Compared to 568 
the BLK wafers (samples B2 and C2), the corresponding DL wafers showed lower porosity 569 
with smaller more compact pores, which confirms the % swelling capacity (section 3.3 and 570 
porosity (section 3.5) results. The very small pores arose because of thicker wall formed 571 
which was attributed to polymer-drug interaction.   572 
 573 
3.5 Pore analysis  574 
Figure S3 (supplementary data) shows the porosity (%) of MET:CAR and MET:CS 575 
wafers relative to total polymer content in the original gels and polymer ratios. The results 576 
demonstrated a decrease in porosity as MET concentration increased in MET:CAR wafers. 577 
However, with the MET:CS formulations, porosity (%) increased slightly with total polymer 578 
concentration and with decreased ratio of MET in the formulations. The highest porosity (%) 579 
values were for MET:CAR wafers were observed for MET:CAR 1:1 (samples B1 and B2) 580 
with values of 98 ± 7% and 96 ± 5%, respectively. For MET:CS wafers the two formulations 581 
that showed highest porosity were samples E2 and F2 (MET:CS ratio 1:1 and 3:1) with 582 
values of 98 ± 12% and 100 ± 8%, respectively.  The lower porosity values for MET:CAR 583 
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formulations can be attributed to collapsed pore capillaries which were observed in SEM 584 
(section 3.4) and thus solvent could not penetrate very well to hydrate the matrix. It was also 585 
observed that for MET:CAR the porosity was decreased at higher concentration of total 586 
polymer due to the increased crosslink density. As described in the SEM (section 3.4), the 587 
MET:CS wafers were more brittle in appearance compared with MET:CAR which could be 588 
attributed to the presence of sub pores, thus facilitating the penetration of the solvent into the 589 
wafers and producing higher porosity % values.  590 
Figure S4 (supplementary data) shows the porosity (%) of DL MET:CAR (samples 591 
DL1 and DL2) wafers. It can be observed that as the concentration of MET increased in the 592 
formulations the porosity % also increased. However, with the CAR:CS 1:1 formulations 593 
(sample DL14), porosity % of the wafers decreased with increase of CS in the formulation 594 
from 68.76 ± 8.54 for sample DL14  to 58.22 ± 7.46% for CAR:CS 1:3 (sample DL13). The 595 
highest porosity % of the DL wafers were observed for MET:CAR 3:1, 1:1 (samples DL1, 596 
DL2) and MET:CS ratio 1:3 (sample DL8) which demonstrated porosity values of 82.45 ± 597 
12.39, 70.82 ± 2.30 and 75.11 ± 6.52% respectively. Generally, the porosity in DL wafers 598 
was less than the corresponding BLK wafers, which might be due to blockage of some 599 
capillaries which slowed down solvent penetration within the DL wafers and confirms the 600 
SEM observations.  601 
 602 
3.6 X-ray powder diffraction  603 
Figure 8a shows the transmission diffractograms of pure starting materials (MET, CS, 604 
CAR and aspirin). The results confirms the amorphous nature of MET with a broad peak at 605 
2θ 10° and 20°, whilst CS also showed the broad peak at 2θ 12° and 25°. CAR confirmed an 606 
amorphous nature with the presence of additional small crystalline sharp peaks at 2θ of 28°, 607 
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40° attributed to inorganic salt impurities from KCl (Prasad, et al., 2009). Aspirin showed its 608 
crystalline nature with the presence of sharp peaks at 2θ of 15°, 20°, 23° and 27°. 609 
 Figures 8b shows the transmission diffractograms of representative BLK MET:CAR 610 
1:1 and 3:1wafers (samples B1, C1, B2 and C2) with no loaded drug BLK. Figure 8c shows 611 
the transmission diffractograms of BLK MET:CS 1:1 and 3:1 wafers (samples E1, F1, E2 and 612 
F2), The diffractogram confirms the amorphous nature of the samples similar to the pure 613 
starting polymers, however, peaks at 2θ 18°, 40°, 50°, 60° and 68° were observed and 614 
attributed to inorganic KCl salt impurities present in CAR as well the presence of a broad 615 
amorphous peak at 2θ 10° and 20° attributed to MET. A small crystalline shoulder peak at 2θ 616 
of 23° was observed for the MET:CAR 3:1 and 1:1 wafers (sample C2 and B2), which could 617 
be attributed to false peak detection arising from compression of the wafer which causes the 618 
leafy networks to be assembled on top of each other and detected as a false crystalline peak 619 
(Okeke & Boateng, 2016). Although it is well known that the amorphous forms are generally 620 
unstable and have the tendency to convert back to more stable crystalline forms, they have 621 
the advantage of higher solubility and therefore higher rates of dissolution which enhance 622 
drug release, absorption and bioavailability. During swelling, amorphous formulations can 623 
absorb more dissolution medium and so the diffusion and the release of the drug can be 624 
accelerated.  625 
 Figure 9 shows the XRD diffractograms of DL formulations; MET:CAR 1:1 and 3:1 626 
(samples DL1, DL2), CAR:CS 1:1 and 1:3 (DL14, DL13) and MET:CS 1:3 (sample DL8) 627 
wafers. The crystalline peaks from aspirin can be observed in all the DL wafers at the same 628 
2θ positions of 15°, 20°, 23° and 27° as shown for the pure drug. Further new crystalline 629 
peaks were formed with the addition of aspirin in the BLK formulations attributed to 630 
alterations within the amorphous polymers, suggesting possible drug-polymer interaction as 631 
previously reported (Haeria, et al., 2015). The results suggest that the high aspirin loaded 632 
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remained largely in the crystalline form and not molecularly dispersed within the polymer 633 
matrix or converted to the amorphous form, and this is expected to enhance its stability in 634 
terms of polymorphic transformation. 635 
 636 
3.6 Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 637 
analysis 638 
As infrared radiation interacts with the bonds between the atoms of a molecule, it is a 639 
good technique to investigate functional groups and their interactions within formulations. 640 
Figure 10a shows the ATR-FTIR spectra of pure MET, CAR, and CS. The bands at 1223 cm-641 
1 and 843 cm-1 were attributed to O-S-O symmetric vibration and the band at 925 cm-1 642 
demonstrated the existence of C-O-C of the 3,-anhydro-D-galactose for CAR. It also showed 643 
bands around 3389, 1036 cm-1 which were attributed to O-H and C-O stretches. The intense 644 
band at 1625 cm-1 was related to water deformation. In the case of MET there was a band 645 
around 3444 cm-1 which correlates to the O-H stretch, an intense band around 1451 cm-1 646 
corresponding to the symmetric vibration of COO, an absorption peak at 2896 cm-1 related to 647 
C-H stretch, the 1053 cm-1 related to C-O stretch and 945 cm-1 corresponding for C-O-C. CS 648 
showed a peak at 2877 cm-1 corresponding to C-H stretch, an intense band at 1607 cm-1 649 
corresponding to water deformation, a peak at 1059 cm-1 that relates to O-H stretch and 1376 650 
cm-1 related to the symmetric vibration of COO. Figure 10a also shows the IR spectra of 651 
aspirin which has three functional groups, a benzene ring (aromatic group), a carboxylic acid 652 
(COOH) group and an ester (R-C=O-O-R) group. The broad and wide peak from 2500 to 653 
3300 cm-1 represents the carboxylic acid (COOH) part of the molecule. The aromatic 654 
functional group is represented by the sharp peak for the C-H stretch around 1710-1780 cm-1, 655 
a medium peak around 1500-1700 cm-1 and a carbonyl group C=O group stretch around 656 
1710-1780 cm-1. The ester group is represented by a C=O stretch at 1735-1750 cm-1.  657 
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The drug loaded wafers represented in [(Figure S2) supplementary data] shows the 658 
interaction of aspirin with the polymers by the broad peak around 2500 cm-1 to 3300 cm-1 659 
representing the COOH group. This interaction is shown by the shifting of the peaks to a high 660 
wavenumber and the reduced peak intensity between 1710 – 1780 cm-1 (aromatic group) of 661 
aspirin.  The bands at 1223 cm-1 and 843 cm-1 were attributed to O-S-O symmetric vibration 662 
and the band at 925 cm-1 demonstrated the existence of C-O-C of the 3,-anhydro-D-galactose 663 
for CAR. It also showed bands around 3389, 1036 cm-1 which were related to O-H and C-O 664 
stretch. The intense band at 1625 cm-1 was related to the deformation of hydrogen bond in 665 
water and described as water deformation band. 666 
  667 
3.7 Thermogravimetric analysis (TGA) 668 
 Table 3 shows the TGA results for both pure starting polymers and the selected 669 
optimized composite BLK composite wafers. The pure compounds were analyzed up to 600 670 
°C and showed a degradation point at around 250 °C, therefore the wafers were analyzed up 671 
to 250 °C. Amorphous polymers which contain water molecules that are bonded to monomer 672 
chains or units have an impact on their glass transition temperature and these polymers 673 
usually undergo spontaneous transformation towards low energy equilibrium states. This is 674 
usually described as relaxation phenomena which indicates structural changes in the materials 675 
and affects other properties such as mechanical properties. The results showed that  the 676 
wafers prepared from MET:CAR 1:1 wafers (samples B1 and B2) had higher residual water 677 
than  MET:CAR ratio 3:1 wafers (samples C1 and C2), which is due to the higher ratio of 678 
MET present in samples C1 and C2  which had a very low residual water of 4.53%. Similar 679 
results were demonstrated with MET:CS 3:1 wafers (samples F1 and F2),  which showed 680 
lower residual water compared to MET:CS 1:1 (samples E1 and E2), which may be attributed 681 
to the amount of MET in the formulation. Keeping an adequate amount of residual moisture 682 
29 
 
content within the wafers was vital as lower water content reduces molecular mobility and 683 
increases shelf-life by avoiding earlier hydration of the active drug (Rodriguez-Spong, et al., 684 
2004). An acceptable residual moisture is required for these formulations as the target drug, 685 
aspirin, is unstable in water due to hydrolysis. The loss of weight observed for all samples 686 
during heating stage occurred between 60 °C and 120 °C and is an indication of the fact that 687 
weight loss was due to bound water (Chen & C, 1999).  688 
As seen in table 3 lower amounts of residual water  were observed in the DL wafers. 689 
The amount of water present in the DL wafers was of 3.92, 3.97, 5.88 and 7.15 % for the 690 
wafers prepared from MET:CAR ratio 1:1 and 3:1, CAR:CS 1:3 and MET:CS 1:3 (samples 691 
DL1, DL2, DL13, DL14 and DL8) respectively.  The % weight loss after 150 °C was 692 
attributed to possible degradation of aspirin and these results helped to inform the DSC 693 
settings and the maximum temperature of 150 °C for the DL wafers was selected in order to 694 
limit possible aspirin degradation.  695 
 696 
3.8 Differential scanning calorimetry (DSC)  697 
DSC was used to define the possible interactions between the materials within the selected 698 
optimized wafers matrix. (Table 4) shows the main DSC thermal transitions observed from 699 
the thermograms of pure MET, CAR and CS all of which showed broad endothermic peaks at 700 
69.72 °C, 95.08 °C and 89.54 °C respectively. The BLK wafers also showed broad 701 
endothermic peaks at 74.53 °C, 65.27 °C and 70.39 °C for the wafers  prepared from 702 
MET:CAR ratios 1:1, 3:1 (samples B2, C2) and MET:CS 1:1 (sample E2) respectively. These 703 
peaks can be attributed to water evaporation as noted by Neto and co-workers, who observed 704 
that water peaks usually fall in the range of 50-150 °C (Neto, et al., 2005). Even though a 705 
heat-cool-heat cycle (involving heating the sample to the highest temperature (200 °C) 706 
without degrading, removing all residual moisture, cooling it down to the starting temperature 707 
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(-50 °C) and then heating again to (200 °C) was used, there was no glass transition observed 708 
thermograms in any of the pure materials, BLK and DL wafers which is attributed to possible 709 
suppression by the endothermic peak from water evaporation (Yoshida, et al., 1992).  The 710 
DSC results for the pure polymers and BLK wafers showed that the formulations can be 711 
considered as amorphous because no melting peak was not observed in the thermograms of 712 
the wafers and it is confirmed by the XRD spectrograms on section 3.6.  713 
DSC was also used to determine the possible interactions between polymers in the 714 
composite  MET:CAR 3:1, 1:1, CAR:CS 1:3, 1:1 and MET:CS 1:3 wafers (samples DL1, 715 
DL2, DL13, DL14 and DL8) and model drug (aspirin) and also confirm their physical form. 716 
Table 4 also shows the DSC profiles of aspirin and representative DL MET:CAR, MET:CS 717 
and CAR:CS wafers. The pure aspirin showed a sharp endothermic peak at 141.94 °C, 718 
indicating melting point of the drug. Aspirin could not be analyzed beyond 160.00 °C for a 719 
re-crystallization peak after melting due to possible aspirin degradation as depicted in the 720 
TGA analysis. Though there was no glass transition peaks in the DL wafers thermograms (as 721 
was the case in the BLK wafers), they all showed melting transition peaks which were 722 
slightly broader than the pure aspirin peak. It can be observed that the melt peak of the DL 723 
wafers shifted from 141.94 °C to a lower temperature of 124.48 °C, 130.68 °C and 131.21 °C 724 
for the DL wafers prepared form MET:CAR 3:1, CAR:CS 1:3 and MET:CS 1:3 (samples 725 
DL1, DL13 and DL8) respectively. This is attributed to physical mixing and interaction of the 726 
aspirin within the polymer matrix confirmed by the FTIR results in section 3.6 which showed 727 
that aspirin interacted with the polymers.  728 
 729 
3.9 In vitro drug release  730 
Drugs can be released from polymer matrix by diffusion through the swollen polymer and 731 
subsequent erosion of the matrix. The drug release may be controlled by diffusion, or by a 732 
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combination of diffusion and erosion or only by erosion of the delivery system (Khan, et al., 733 
2016). Before the drug dissolution studies, the drug loading (assay) in each wafer sample was 734 
determined using SS and PBS. The dissolution profile (figure 11a) for DL wafers in PBS 735 
solution pH 6.8 ± showed that during the early stage of dissolution there was an almost linear 736 
release profile, which was confirmed by fitting the data to Korsmeyer-Peppas equation, 737 
(supplementary data section S1, table S2). It was observed that for the  MET:CAR 1:1 and 738 
3:1 wafers (samples DL1 and DL2) the release was 70.8 % and 63.3 % respectively within 20 739 
minutes. For the CAR:CS 1:1 (sample DL14) the release of the drug was 64.8 % within 20 740 
minutes and for CAR:CS 1:3 (sample DL13) the release was of 90.5 % within the same time 741 
period. The release of MET:CS (sample DL8) was of 100.0 % within 20 minutes.  742 
The dissolution profile of DL wafers were also observed in (figure 11b) using SS at 743 
pH 6.8 ± 0.1. The SS helps to accurately mimic the environment of the oral cavity such as pH 744 
and ionic strength. The % release was observed to be lower than in PBS with only 41.9 % 745 
released for MET:CAR 1:1 (sample DL1) and 42.8% for MET:CAR 3:1(sample DL2). For  746 
the CAR:CS 1:3 wafers (samples DL13), 20.0 % was released in the first 20 minutes and 747 
gradually increased to 32.9 % at 60 minutes and 42.0% at 90 minutes and then remained 748 
fairly constant till 120 minutes.  749 
 Though the DL wafers appeared to show some controlled release in the two 750 
dissolution media over 2 hours, PBS showed higher cumulative release than SS which is 751 
related to the effect of SS on the initial swelling of the polymer matrix and subsequent drug 752 
diffusion as well as matrix erosion. The drug release was faster in PBS than in SS due to the 753 
difference in osmotic pressure and ionic strength as SS contains more sodium, chloride and 754 
sulfate ions than PBS. It was observed that the formulations with lower swelling capacity,  755 
which disintegrated within 2 to 30 minutes  CAR:CS 1:1 and 1:3 (samples DL14, DL13) and 756 
MET:CS 1:3(sample DL8)) showed a higher release profile than  MET:CAR 1:1 and 3:1 the 757 
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formulations (samples DL1 and DL2) which correlated very well with the swelling capacity 758 
data described in section 3.3.  759 
Wafers prepared from  MET:CAR 3:1 (sample DL1) had a lower release compared to 760 
sample DL2  which is due to the increased MET in the formulations which helps to increase 761 
the viscosity and density of the wafers thus controlling drug diffusion and release. This was 762 
also observed in swelling capacity where sample DL2  showed a higher swelling capacity and 763 
also due to higher porosity which allowed more media to penetrate the polymeric matrix as 764 
was observed in section 3.3.7.  765 
Overall, the drug release profiles shows the formulations fall into two distinct 766 
categories with the DL MET:CAR formulations showing relatively slower drug release due to 767 
their swelling nature due to the presence of MET, whilst the CAR:CS formulations generally 768 
disintegrated rapidly upon contact with dissolution medium and consequently releasing the 769 
contained drug relatively quickly. This will suggest that once applied in the oral cavity, the 770 
two formulations will behave differently with the CAR:CS wafers most likely disintegrating 771 
rapidly into a free flowing gel that will be swallowed for gastric absorption. On the other 772 
hand the MET:CAR wafers will most likely remain in the oral cavity including the buccal 773 
mucosa, long enough to allow pre-gastric absorption through the buccal mucosa and 774 
subsequently swallowing of the remaining dose present in saliva. However, this will need to 775 
be further investigated in an in vivo study.  776 
4.0 Conclusion  777 
Composite MET:CAR and CAR:CS and MET:CS loaded with aspirin have been successfully 778 
formulated as potential oral and buccal delivery systems for low dose aspirin. The use of 779 
composite polymeric systems was implemented to increase the functional properties of the 780 
polymeric dosage forms. The results demonstrated that mucoadhesion, physico-781 
characteristics, swelling capacity and microscopic structure were influenced by higher 782 
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concentration of MET and the total amount of total polymer weight which increased the 783 
density of the formulations. The DL wafers did not show highly porous internal morphology, 784 
instead they showed very small pores in a thick walled matrix due to polymer-drug 785 
interactions. . The aspirin was released much faster in PBS than in SS which is attributed to 786 
the matrix of polymeric wafers and interactions with the two media as a result of the 787 
differences in ionic strength. By fitting the dissolution data for PBS and SS into Korsmeyer-788 
Peppas equation, it was concluded that the drug release were controlled by diffusion or by 789 
combination of diffusion and erosion depending on the formulation composition and ionic 790 
environment (PBS or SS). Wafers prepared from MET:CAR 1:1 and 3:1 (samples DL2 and 791 
DL1) and CAR:CS 3:1 and 1:1 (samples DL13 and DL14) and MET:CS 3:1 (sample DL8) 792 
loaded with 75 mg aspirin are good candidates for the delivery of low dose aspirin for the 793 
elderly people, based on visual and physico-chemical characterization. Based on the swelling 794 
and drug dissolution results, The MET:CAR 3:1 wafer (DL1) with longer swelling time could 795 
be used for controlled release of aspirin via the buccal mucosa (pregastric absorption), whilst 796 
CAR:CS 1:1 wafer (DL14) can be used as a fast disintegrating delivery system that will 797 
combine initial buccal (pregastric) absorption and subsequent GIT (gastric) absorption 798 
swallowing the remaining free flowing gel.  799 
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Table 1. Polymeric solutions for preparing BLK freeze-dried formulations in H2O 
Sample name  MET  
 (g) 
CAR 
  (g) 
Polymer ratio Total excipient content in 
polymeric solution  
(% w/v) 
Sample A 0.38 1.12 1:3 1.50 
Sample B 0.75 0.75 1:1 1.50 
Sample C 1.12 0.38 3:1 1.50 
Sample A1 0.50 1.50 1:3 2.00 
Sample B1 1.00 1.00 1:1 2.00 
Sample C1 1.50 0.50 3:1 2.00 
Sample A2 0.63 1.87 1:3 2.50 
Sample B2 1.25 1.25 1:1 2.50 
Sample C2 1.87 0.63 3:1 2.50 
     
Sample name  MET  
 (g) 
CS 
  (g)  
Polymer ratio Total excipient content in 
polymeric solution  
(% w/v) 
Sample D 0.38 1.12 1:3 1.50 
Sample E 0.75 0.75 1:1 1.50 
Sample F 1.12 0.38 3:1 1.50 
Sample D1 0.50 1.50 1:3 2.00 
Sample E1 1.00 1.00 1:1 2.00 
Sample F1 1.50 0.50 3:1 2.00 
Sample D2 0.63 1.87 1:3 2.50 
Sample E2 1.25 1.25 1:1 2.50 
Sample F2 1.87 0.63 3:1 2.50 
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Table 2. Polymeric solutions for preparing DL freeze-dried formulation in 100 ml of 45% v/v 
ethanolic solution  
 
 
 
 
Sample name  MET  
 (g) 
CAR 
 (g) 
LMW CS  
  
 
(g) 
Polymer ratio Total excipient 
content in polymeric 
solution  
(% w/v) 
Sample DL1 1.87 0.63 0.00 3:1 2.50 
Sample DL2 1.25 1.25 0.00 1:1 2.50 
Sample DL3 1.25 0.63 0.63 2:1:1 2.50 
Sample DL4 0.63 1.25 0.63 1:2:1 2.50 
Sample DL5 0.63 0.63 1.25 1:1:2 2.50 
Sample DL6 1.87 0.00 0.63 3:1 2.50 
Sample DL7 1.25 0.00 1.25 1:1 4.00 
Sample DL8 3.00 0.00 1.00 1:3 4.00 
Sample DL9 0.00 1.87 0.63 3:1 2.50 
Sample DL10 0.00 0.63 1.87 1:3 2.50 
Sample DL11 0.00 1.25 1.25 1:1 2.50 
Sample DL12 0.00 3.00 1.00 3:1 4.00 
Sample DL13 0.00 1.00 3.00 1:3 4.00 
Sample DL14 0.00 2.00 2.00 1:1 4.00 
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Table 3.  Weight loss % from TGA analyses of pure compounds, BLK wafers and DL wafers 
at 120 °C. 
 
Formulations (BLK wafers)/starting materials Weight loss % 
Metolose 4.53 
Carrageenan 14.5 
Chitosan 18.5 
Sample E1 11.67 
Sample E2 11.59 
Sample F1 2.24 
Sample F2 8.62 
Sample B1 11.50 
Sample B2 9.93 
Sample C1 8.11 
Sample C2 7.57 
 
DL wafers / aspirin 
Aspirin  0.67 
Sample DL2 3.92 
Sample DL1 3.97 
Sample DL13 5.88 
Sample DL8 7.15 
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Table 4. Summary of temperature and heat changes observed for the endothermic transition 
observed during DSC analysis for pure materials, BLK wafers and DL wafers.  
 
Materials / formulations  Onset °C  Peak °C ΔH (J/g)  
Pure materials 
Metolose 23.57 69.72 89.11 
Carrageenan 42.72 95.08 234.50 
LMW chitosan 33.67 89.54 329.70 
Aspirin  139.08 141.94 170.50 
BLK wafers  
Sample B2 50.07 74.57 247.40 
Sample C2 20.21 65.27 154.50 
Sample E2 25.63 70.39 199.10 
Formulations Onset °C Peak °C ΔH (J/g) 
DL wafers 
Sample DL1 112.95 124.48 103.70 
Sample DL13 121.31 130.68 126.60 
Sample DL8 122.93 131.21 120.40 
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Figure 1. Resistance to compression (hardness) profiles of BLK composite wafers (a) 916 
MET:CS, (b) MET:CAR wafers and (c) DL composite wafers. The test was performed using 917 
a Texture Analyser fitted with a 5 kg load cell. Each wafer was compressed in 5 different 918 
positions, using a 2mm probe to a depth of 1mm and speed of 1 mm/sec with the instrument 919 
in compression mode (mean ± SD, n = 3).  920 
  921 
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 922 
 923 
 924 
Figure 2. Mucoadhesive profile of BLK composite (a) MET:CAR and (b) MET:CS wafers in 925 
SS and PBS . The test was performed using a Texture Analyser fitted with a 5 kg load cell in 926 
adhesive mode. The probe with the sample attached was lowered to make contact with the 927 
model mucosa surface with an applied force of 1.0 N and was detached after 60 seconds 928 
contact. Three replicates were performed for each sample (mean ± SD, n = 3).  929 
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 930 
 931 
(a) SS 932 
 933 
(b) PBS 934 
Figure 3. Mucoadhesion profile of aspirin loaded wafers in (a) SS and (b) PBS. The test was 935 
performed using a Texture Analyser fitted with a 5 kg load cell in adhesive mode. The probe 936 
with the sample attached was lowered to make contact with the model mucosa surface with 937 
an applied force of 1.0 N and was detached after 60 seconds contact. Three replicates were 938 
performed for each sample (mean ± SD, n = 3). 939 
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Figure 4. Swelling profiles BLK wafers - (a)  MET:CS 3:1 and 1:1 (samples E1, F1, E2 and F2) in SS, (b)  MET:CS 3:1, 1:1 and 1:3 (samples 941 
D1, E1, F1, D2, E2 and F2) in PBS, (c) MET:CAR ratio 1:3, 1:1 and 3:1 (samples A1, B1, C1, A2, B2 and C2) in SS and (d) MET:CAR ratio 942 
1:3, 1:1 and 3:1 (samples A1, B1, C1, A2, B2 and C2) in PBS. The swelling capacity was determined at a temperature of 37 ± 0.1°C. It was 943 
determined for three replicates (mean ± SD, n = 3) and calculated using equation 6.  944 
48 
 
 945 
(a) PBS 946 
 947 
(b) SS 948 
Figure 5. Swelling profiles of DL wafers (a) MET:CAR ratio 1:1, and 3:1 (samples DL2 and 949 
DL3), CAR:CS ratio 1:3 and 1:1 (samples DL13 and DL14) and MET:CS ratio 1:3 (sample 950 
DL8) in PBS (b) MET:CAR ratio 1:1 and 3:1 (samples DL2 and DL3), CAR:CS ratio 1:3 and 951 
1:1 (samples DL13 and DL14) and MET:CS ratio 1:3 (sample DL8) in SS. The swelling 952 
capacity was determined at a temperature of 37 ± 0.1°C. It was determined for three 953 
replicates (mean ± SD, n = 3) and calculated using equation 6.  954 
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 956 
 957 
Figure 6. SEM images showing the internal porous structure and surface morphology of the 958 
BLK wafers [(a) MET:CAR 1:1 (sample B1) (b)  MET:CAR 3:1 (sample C1) (c) MET:CAR 959 
1:1 (sample B2) (d)  MET:CAR 3:1 (sample C2)  (e)  MET:CS 1:1 (sample E1) (f) MET:CS 960 
3:1 (sample F1) (g)  MET:CS 1:1 (sample E2) and (h)  MET:CS 3:1 (sample F2)]. The 961 
surface morphology was analysed using a Hitachi SU8030. The wafers were coated with 962 
chromium using a Sputter Coater and analysed at 5.0 kV accelerating voltage.  963 
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 965 
Figure 7. SEM images showing the internal porous structure and surface morphology of the 966 
(a) aspirin and DL wafers  [(b)  MET:CAR 3:1 (sample DL1) (c) MET:CAR 1:1 (sample DL 967 
2) (d)  MET:CS 1:3 (sample DL8) (e) CAR:CS 1:3 (sample DL13) and (f) CAR:CS 1:1 968 
(sample DL14)]. The surface morphology was analysed using a Hitachi SU8030. The wafers 969 
were coated with chromium using a Sputter Coater and analysed at 5.0 kV accelerating 970 
voltage.  971 
  972 
51 
 
 973 
(a) 974 
 975 
(b) 976 
Operations: Y Scale Add 2656 | Y Scale Add 1995 | Y Scale Mul  0.333 | Import
Car
Operations: Y Scale Add 6979 | Y Scale Mul  0.167 | Import
Pure Aspirin
Operations: Y Scale Add -141 | Import
LMW CS
Operations: Y Scale Add 622 | Import
Metolose
L
in
 (
C
o
u
n
ts
)
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
2-Theta - Scale
5 10 20 30 40 50
Aspirin 
Carrageenan
Metolose
LMW chitosan
52 
 
 977 
(c) 978 
Figure 8. XRD-transmission diffractograms of (a) pure starting materials (b) MET:CAR 979 
wafers (c) MET:CS wafers The diffractograms were obtained using a D8 Advantage X-ray 980 
diffractometer. The samples were analysed in transmission mode at a diffraction angle 981 
ranging from 5° to 50° 2θ, step size 0.04°, and scan speed of 0.4 s/step.  982 
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 988 
 989 
Figure 9. XRD-transmission diffractograms of DL MET:CAR, MET:CS and CAR:CS 990 
wafers. The diffractograms were obtained using a D8 Advantage X-ray diffractometer. The 991 
samples were analysed in transmission mode at a diffraction angle ranging from 5° to 50° 2θ, 992 
step size 0.04°, and scan speed of 0.4 s/step. 993 
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 1002 
(c) 1003 
Figures 10. ATR-FTIR spectra of (a) pure starting materials and API, (b) BLK composite MET:CAR wafers, (d) composite MET:CS wafers. 1004 
The spectrums were obtained from a Perkin Elmer Spectrum equipped with a diamond universal ATR unit. The resolution of the samples were 1005 
recorded at 4 cm-1 within the range of 500-4000 cm -1. 1006 
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(a)  1008 
 1009 
(b) 1010 
Figure 11. Drug dissolution profiles of aspirin loaded wafers prepared from ethanolic gels 1011 
containing MET:CAR 1:1 and 3:1 (samples DL2 and DL1), CAR:CS 1:3 and 1:1 (samples 1012 
DL13 and DL14) and MET:CS 1:3 (sample DL8) in (a) PBS at pH 6.8 ± 0.1 and (b) SS at pH 1013 
6.8 ± 0.1 (mean ± SD, n = 3). 1014 
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